Certain drugs are known to elicit photosensitivity side effects. A satisfactory understanding of the involved mechanistic aspects is necessary to anticipate the photosensitizing potential. We have used tiaprofenic acid (TPA), a photosensitizing nonsteroidal antiinflammatory drug, to illustrate the methodology followed to address this problem. After studying the photophysical and photochemical properties of TPA, the attention has been directed towards the reactivity of its lowest lying π−π* triplet with biomolecules. Photosensitized lipid peroxidation occurs by a mixed type I (radicals) and type II (singlet oxygen) mechanism. In the case of proteins, the photosensitized reactions include Tyr, Trp, and His photodegradation, protein-protein photocrosslinking and drug-protein photobinding. This involves direct quenching of the drug triplet by the amino acid residues (Tyr and Trp) or by oxygen, followed by singlet oxygen oxidation (His and Trp). With DNA, the studies have included comet assay, induction of single-strand breaks in supercoiled DNA, and reaction with 2'-deoxyguanosine and thymidine. Product studies, together with time-resolved measurements, have shown that the fastest reaction occurs with purine bases, by a mechanism involving both radical and singlet oxygen processes. The employed methodology can be of general use to investigate the mechanistic aspects of photosensitization by drugs.
PHOTOSENSITIVITY SIDE EFFECTSThe combined action of drugs and sunlight on patients can produce both desired and undesired effects [1]. Thus, PUVA-therapy (psoralenes plus UVA-radiation) has long been employed for the treatment of psoriasis, while porphyrins are currently being introduced for the photodynamic therapy (PDT) of cancer or other diseases. By contrast, there is also a significant number of reports indicating that a variety of drugs can elicit undesired side effects, such as phototoxicity, photoallergy, or photocarcinogenicity [2,3].The photobiological risk associated with the use of drugs depends on environmental and individual factors (climate, height on the sea level, type of skin, etc.). On the other hand, the photosensitizing potential is enhanced in the case of topically administered drugs or when the field of application is dermatology or ophthalmology. Considering all these factors, in a number of cases it may be advisable to evaluate the photobiological risk of a new drug candidate before its introduction in the market [3].
The mechanistic approach to risk predictionIn order to anticipate the appearance of photosensitivity side effects, a mechanistic understanding of the involved phenomena is necessary. Absorption of sunlight by drugs leads to their excited states. These can proceed further to afford drug-derived reactive intermediates or, under aerobic conditions, reactive oxygen species. Any of the above short-lived chemical entities may be able to interact with biological *Lecture presented at the